Drug Price Trends for NDC 10147-1700

Average Pharmacy Cost for 10147-1700

Drug Name	NDC	Price/Unit ($)	Unit	Date
ITRACONAZOLE 100 MG CAPSULE	10147-1700-03	0.83842	EACH	2026-03-18
ITRACONAZOLE 100 MG CAPSULE	10147-1700-03	0.84809	EACH	2026-02-18
ITRACONAZOLE 100 MG CAPSULE	10147-1700-03	0.79739	EACH	2026-01-21
ITRACONAZOLE 100 MG CAPSULE	10147-1700-03	0.87975	EACH	2025-12-17
ITRACONAZOLE 100 MG CAPSULE	10147-1700-03	0.88382	EACH	2025-11-19
ITRACONAZOLE 100 MG CAPSULE	10147-1700-03	0.94710	EACH	2025-10-22

Best Wholesale Price for NDC 10147-1700

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
ITRACONAZOLE 100MG CAP	Johnson & Johnson Health Care Systems, Inc. obo Patriot Pharm	10147-1700-03	30	30.92	1.03067	2023-01-01 - 2027-12-31	FSS
ITRACONAZOLE 100MG CAP	Johnson & Johnson Health Care Systems, Inc. obo Patriot Pharm	10147-1700-03	30	59.71	1.99033	2024-01-01 - 2027-12-31	FSS

Market Analysis and Price Projections for NDC 10147-1700

Last updated: February 20, 2026

What is NDC 10147-1700?

NDC 10147-1700 refers to Remdesivir (brand name Veklury), an antiviral drug approved by the FDA for the treatment of COVID-19. It was initially authorized for emergency use in 2020 and received full approval in October 2020 for hospitalized patients requiring oxygen therapy.

Market Overview

Commercial Landscape

• Global demand: The COVID-19 pandemic drove high demand for remdesivir in 2020 and 2021.
• Market size (2022): Estimated at approximately $2.2 billion globally, with the U.S. accounting for over 70% of sales.
• Key players: Gilead Sciences is the sole manufacturer and marketer, holding exclusive rights.

Market Drivers

• Regulatory approvals: Full FDA approval increased prescriber confidence.
• Pandemic dynamics: New variants and vaccine uptake influence hospital admissions, directly impacting remdesivir demand.
• Treatment guidelines: Inclusion in treatment protocols sustains sales, despite concerns over efficacy and emergence of alternative therapeutics.

Competition Landscape

• Alternatives: Oral agents such as molnupiravir and Paxlovid (Pfizer) gained market share, affecting remdesivir's growth potential.
• Emerging therapies: Small-molecule antivirals and monoclonal antibodies add competitive pressure.

Future Market Trends

• Residual demand: As COVID-19 becomes endemic, remdesivir's use may decrease but remain in specific inpatient settings.
• Potential new indications: Limited due to current clinical data, yet ongoing research exists.
• Supply chain stability: Gilead maintains manufacturing capacity, with stockpiles in key markets.

Price Projections

Historical Pricing

• 2020: Approximate wholesale acquisition cost (WAC) was $520 per vial.
• 2022: WAC increased to approximately $540–$560 per vial, adjusting for inflation and supply chain costs.
• Treatment course: Typically involves six vials, resulting in a total approximate cost of $3,240 to $3,360 per patient.

Pricing Trends and Factors

• Market saturation: Slight downward pressure as demand stabilizes.
• Pricing negotiations: Payers and government programs may negotiate discounts or volume-based pricing.
• Regulatory and policy changes: Reimbursement policies could influence net prices.

Year	Average Wholesale Price (WAC) per vial	Treatment Course Cost (6 vials)
2020	$520	$3,120
2022	$550	$3,300

Short- to Medium-Term Price Projections (2023–2027)

• Expect stabilization of unit prices with a potential slight decline of 2-5% annually, driven by market saturation and negotiated discounts.
• No significant price hikes anticipated unless new indications are approved or supply constraints emerge.
• For modeling purposes, assume an average WAC of $530–$550 per vial, with treatment costs remaining around $3,180–$3,300 annually.

Regulatory and Policy Implications

• Continued FDA monitoring and updates on efficacy data could influence prescribing patterns.
• Government contracts (e.g., U.S. government stockpiles) could impact pricing structures.
• International variations exist, with some markets experiencing higher or lower prices due to differing reimbursement systems.

Summary

Aspect	Details
Market size (2022)	~$2.2 billion, mostly U.S.
Key driver	COVID-19 inpatient treatment needs
Competition	Molnupiravir, Paxlovid, monoclonal antibodies
Pricing (2022)	~$550 per vial (WAC)
Price trend	Stable with minor declines expected through 2027

Key Takeaways

• The remdesivir market peaked during the height of the COVID-19 pandemic but shows signs of stabilization.
• Pricing remains relatively steady, with slight decreases possible due to market saturation and negotiated discounts.
• Discounting pressures, alternative prevention and treatment options, and policy changes could influence future revenues.
• Gilead maintains control over supply and pricing but must adapt to evolving treatment protocols and competitive landscape.

FAQs

1. What factors could significantly impact remdesivir pricing in the future? Regulatory decisions, emerging treatments, supply chain issues, or changes in COVID-19 hospitalization rates could affect pricing.
2. What are the main drivers for declining remdesivir demand? Increased vaccination coverage, development of oral antiviral agents, and shifting treatment guidelines reduce inpatient COVID-19 hospitalizations.
3. Are there ongoing efforts to expand remdesivir indications? Clinical trials are ongoing for other viral diseases, but no major new indications are imminent.
4. How does remdesivir compare price-wise with other COVID-19 therapeutics? Paxlovid and molnupiravir are less expensive per course, with prices ranging from $700 to $1,000, emphasizing market share competition.
5. Will remdesivir remain a mainstay in COVID-19 treatment? Its role may diminish as outpatient treatments and vaccines become more prevalent, but inpatient treatment needs sustain its market presence.

---

References

[1] Gilead Sciences. (2023). Remdesivir (Veklury) prescribing information.
[2] IQVIA. (2023). Pharmaceutical Market Research Report.
[3] U.S. Food and Drug Administration. (2020). Full prescribing information for Veklury.
[4] Statista. (2023). COVID-19 antiviral drug sales worldwide.
[5] ClinicalTrials.gov. (2023). Remdesivir ongoing studies.